Jade Biosciences (JBIO) CFO granted 226,875 options and 37,813 RSUs

Rhea-AI Filing Summary

Jade Biosciences Chief Financial Officer Bradford D. Dahms received new equity awards on February 12, 2026. He was granted 37,813 shares of common stock in the form of restricted stock units at no cash cost, each representing a right to one share.

These RSUs vest in four equal installments on each of the first four anniversaries of February 15, 2026, contingent on continued service. Dahms was also granted stock options for 226,875 shares of common stock with a $14.81 exercise price, granted at no cost.

One quarter of the options vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, also subject to his continued service. All reported holdings are shown as directly owned.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dahms Bradford D.

(Last) (First) (Middle)

C/O JADE BIOSCIENCES, INC.

221 CRESCENT ST., BLDG. 23, STE. 105

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jade Biosciences, Inc. [ JBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		A		37,813(1)	A	$0	37,813	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.81	02/12/2026		A		226,875		(2)	02/11/2036	Common Stock	226,875	$0	226,875	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

2. This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Elizabeth Balta, as attorney-in-fact for Bradford D. Dahms	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider equity awards did Jade Biosciences (JBIO) grant to its CFO?

Jade Biosciences granted its CFO Bradford D. Dahms 37,813 restricted stock units and stock options on 226,875 shares. The RSUs and options were awarded at no cash cost and vest over several years, subject to his continued service with the company.

How do the Jade Biosciences (JBIO) CFO’s 37,813 RSUs vest over time?

The 37,813 RSUs granted to Jade Biosciences’ CFO vest in four equal parts on each of the first four anniversaries of February 15, 2026. Vesting is contingent on his continued service to the company on each applicable vesting date.

What are the key terms of the 226,875 stock options granted by Jade Biosciences (JBIO)?

The 226,875 stock options give the CFO the right to buy Jade Biosciences common stock at a $14.81 exercise price. One quarter vests on February 15, 2027, with the rest vesting in equal monthly installments over the following three years.

Are the Jade Biosciences (JBIO) CFO’s new RSUs and options subject to continued service?

Yes. Both the 37,813 RSUs and the 226,875 stock options vest only if the CFO remains in service. Each scheduled vesting date requires continued service to Jade Biosciences for the corresponding portion to vest and become earned.

Did the Jade Biosciences (JBIO) CFO buy these shares on the open market?

No. The Form 4 shows these as grants, not open-market purchases. The RSUs and stock options were awarded at a stated price of $0 per derivative security, with the options carrying a $14.81 exercise price for future share purchases.

How many Jade Biosciences (JBIO) derivative securities does the CFO hold after this grant?

Following the reported transaction, the CFO beneficially owns 226,875 stock options. These options relate to potential future purchases of Jade Biosciences common stock, subject to the vesting schedule and payment of the $14.81 exercise price per share.